At 27 months old—a ripe age for a mouse—those treated with a single injection of gene therapy in Barcelona began moving with the vigor of youth, their organs functioning as if time had slowed. At the Center for Animal Biotechnology and Gene Therapy (CBATEG) at the Universitat Autònoma de Barcelona, Professor Fatima Bosch and her team have achieved a breakthrough in the science of aging: a one-time gene therapy that extends both lifespan and health span in geriatric mice. This isn’t just about living longer—it’s about living better. As populations age worldwide and age-related diseases place growing strain on healthcare systems, the idea of extending disease-free life is no longer science fiction but a pressing scientific pursuit. The therapy uses an adeno-associated viral vector (AAV) to prompt skeletal muscle to produce fibroblast growth factor 21 (FGF21), a metabolic regulator with far-reaching effects. When injected just once into elderly male and female mice, the treatment triggered systemic improvements that lasted for the remainder of their lives.
The numbers are striking: treated mice lived 20.54% longer than their untreated counterparts, a dramatic leap in a species with a typical two- to three-year lifespan. But more remarkable than longevity was the quality of those added months. The therapy normalized body weight and fat accumulation, enhanced insulin sensitivity, and boosted energy expenditure. In the liver, it prevented amyloidosis and preserved detoxification capacity. Kidneys showed no signs of age-related decline, with markers of damage reversed. Hearts avoided fibrosis and maintained structural integrity. Even the brain benefited—memory and learning improved to levels seen in young mice. Physical performance, from strength to coordination, remained robust, defying the usual decay of old age.
These benefits stem from deep cellular reprogramming. Transcriptomic analyses revealed enhanced mitochondrial function across tissues, with upregulated pathways for energy production. Proteostasis—the delicate balance of protein synthesis and degradation—was restored, a key factor in cellular health. In the liver, detoxification enzymes were regulated to youthful levels. Each organ adapted in a coordinated way to resist the wear and tear of time. As Bosch notes, this therapy doesn’t just target one symptom—it reshapes the body’s metabolic landscape.
The implications extend beyond mice. This same FGF21-based therapy has already shown promise in reversing metabolic dysfunction-associated steatohepatitis (MASH) in preclinical models, and with FDA approval, human clinical trials for MASH are set to begin in 2026. If even a fraction of these effects translates to people, the potential to delay or prevent multiple age-related conditions with a single intervention could redefine how we approach aging. For now, in a lab in Barcelona, old mice are moving, thinking, and thriving like the young—a quiet revolution unfolding, one injection at a time.